home / stock / cyad / cyad news

CYAD News and Press, Celyad SA From 08/10/22

Stock Information
Company Name: Celyad SA
Stock Symbol: CYAD
Market: NASDAQ
Menu
CYAD CYAD Quote CYAD Short CYAD News CYAD Articles CYAD Message Board
Get CYAD Alerts

News, Short Squeeze, Breakout and More Instantly...
CYAD - BLUE, INVZ and AQST are among pre market gainers

Euro Tech Holdings Company ( CLWT ) +39% . SilverSun Technologies ( SSNT ) +28% . Aethlon Medical ( AEMD ) +19% CEO Chuck Fisher on Q1 2023 Results - Earnings Call Transcript. The Trade Desk ( TTD ) +16% Inc. 2023 Q2 - Results - Earnings C...
CYAD - Celyad Oncology SA's (CYAD) CEO Michel Lussier on Q2 2022 Results - Earnings Call Transcript

Celyad Oncology SA (CYAD) Q2 2022 Earnings Conference Call August 5, 2022 8:00 A.M. ET Company Participants Sara Zelkovic - Director, Communications and Investor Relations Michel Lussier - Interim Chief Executive Officer Charlie Morris - Chief Medical Officer ...

CYAD - Celyad Oncology GAAP EPS of -Euro0.62

Celyad Oncology press release ( NASDAQ: CYAD ): 1H GAAP EPS of -€0.62. As of June 30, 2022, the Company had cash and cash equivalents of €14.4 million Shares -5% AH For further details see: Celyad Oncology GAAP EPS of -€0.62

CYAD - Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM) In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold for the T-cell-inhibit...
CYAD - SENS, YELL and ABEO are among pre market gainers

InVivo Therapeutics Holdings ( NVIV ) +106% . GreenLight Biosciences ( GRNA ) +94% . NanoViricides ( NNVC ) +48% stock skyrockets 50% on start of drug development program for monkeypox. Exicure ( XCUR ) +39% . Global Blood Therapeuti...

CYAD - Snowflake, Oatly Group among premarket losers' pack

Eliem Therapeutics ELYM -25% on report to discontinue development of lead asset as mid-stage pain trial fails . Mobile Global Esports (MGAM) -14% . Senti Biosciences ( SNTI ) -10% . Celyad Oncology ( CYAD ) -11% . Eos Energy Enterprises EOSE...

CYAD - TOUR, MDIA and FXLV among mid-day movers

Gainers: Liberty TripAdvisor ( LTRPB ) +209% . Virax Biolabs Group ( VRAX ) +130% . Qurate Retail ( QRTEB ) +80% . MediaCo ( MDIA ) +67% . Nanobiotix  ( NTX ) +47% . Aethlon Medical ( AEMD ) +46% . GeoVax ( ...
CYAD - Virax, Aethlon top healthcare gainers; while Otonomy, Kazia lead losers' pack

Gainers: Virax Biolabs ( VRAX ) +62% . Aethlon Medical ( AEMD ) +46% . GeoVax Labs ( GOVX ) +46% . Celyad Oncology ( CYAD ) +40% . Outset Medical ( OM ) +28% . Losers: Otonomy ( OTIC ) -77% . Kazia Therapeu...

CYAD - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off Monday with a breakdown of the biggest pre-market stock movers traders will want to watch! We’ve got clinical trial data, public debuts, and more to...

CYAD - Celyad stock soars 35% as FDA lifts hold on colorectal cancer trial of CYAD-101/Keytruda

Celyad Oncology ( NASDAQ: CYAD ) said the the U.S. Food and Drug Administration (FDA) a lifted a clinical hold on a phase 1b trial of its CAR T cell therapy CYAD-101, after the company made changes to the eligibility criteria for the trial. In March, the FDA placed a ...
Previous 10 Next 10